Structure-Based Discovery of Novel Chemotypes for Adenosine A2A Receptor Antagonists

被引:200
作者
Katritch, Vsevolod [1 ,2 ]
Jaakola, Veli-Pekka [1 ]
Lane, J. Robert [3 ]
Lin, Judy [3 ]
IJzerman, Adriaan P. [3 ]
Yeager, Mark [2 ,4 ]
Kufareva, Irina [1 ]
Stevens, Raymond C. [1 ]
Abagyan, Ruben [1 ]
机构
[1] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA
[3] Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-2300 RA Leiden, Netherlands
[4] Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA
基金
美国国家卫生研究院;
关键词
PROTEIN-COUPLED RECEPTOR; DRUG DISCOVERY; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; PARTIAL AGONISTS; LIGAND DOCKING; BINDING-SITE; POTENT; GPCR; ACCURATE;
D O I
10.1021/jm901647p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The recent progress in crystallography of G-protein coupled receptors Opens an unprecedented venue for structure-based GPCR drug discovery. To test efficiency of the structure-based approach, we performed molecular docking and virtual ligand screening (VLS) of more than 4 million commercially available "drug-like" and "lead-like" compounds against the A(2A)AR 2.6 angstrom resolution crystal structure. Out of 56 high ranking compounds tested in A(2A)AR binding assays, 23 showed affinities under 10 mu M, 11 of those had sub-mu M affinities and two compounds had affinities under 60 nM. The identified hits represent at least 9 different chemical scaffolds and are Characterized by very high ligand efficiency (0.3-0.5 kcal/mol per heavy atom). Significant A(2A)AR antagonist activities were confirmed for 10 out of 13 ligands tested in Functional assays. High success rate, novelty, and diversity of the chemical scaffolds and strong ligand efficiency of the A(2A)AR antagonists identified in this study suggest practical applicability of receptor-based VLS in GPCR drug discovery.
引用
收藏
页码:1799 / 1809
页数:11
相关论文
共 56 条
[1]   BIASED PROBABILITY MONTE-CARLO CONFORMATIONAL SEARCHES AND ELECTROSTATIC CALCULATIONS FOR PEPTIDES AND PROTEINS [J].
ABAGYAN, R ;
TOTROV, M .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (03) :983-1002
[2]  
Abagyan R, 2009, ICM MANUAL 3 0
[3]  
Ballesteros J. A., 1995, Neuroscience Methods, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471]
[4]   New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist n-ethylcarboxamidoadenosine [J].
Beukers, MW ;
Chang, LCW ;
Künzel, JKVD ;
Mulder-Krieger, T ;
Spanjersberg, RF ;
Brussee, J ;
Ijzerman, AP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (15) :3707-3709
[5]  
Blackburn Michael R, 2009, Handb Exp Pharmacol, P215, DOI 10.1007/978-3-540-89615-9_8
[6]   Four-Dimensional Docking: A Fast and Accurate Account of Discrete Receptor Flexibility in Ligand Docking [J].
Bottegoni, Giovanni ;
Kufareva, Irina ;
Totrov, Maxim ;
Abagyan, Ruben .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :397-406
[7]   Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors [J].
Brown, J ;
Brown, CA .
VASCULAR PHARMACOLOGY, 2002, 39 (06) :309-315
[8]   Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile [J].
Cacciari, Barbara ;
Bolcato, Chiara ;
Spalluto, Giampiero ;
Klotz, Karl-Norbet ;
Bacilieri, Magdalena ;
Deflorian, Francesca ;
Moro, Stefano .
PURINERGIC SIGNALLING, 2007, 3 (03) :183-193
[9]   Ligand docking and structure-based virtual screening in drug discovery [J].
Cavasotto, Claudio N. ;
Orry, Andrew J. W. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (10) :1006-1014
[10]   2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists [J].
Chang, Lisa C. W. ;
Spanjersberg, Ronald F. ;
Kunzel, Jacobien K. Von Frijtag Drabbe ;
Brussee, Johannes ;
IJzerman, Adriaan P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (10) :2861-2867